Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 23,947

Document Document Title
WO/2017/013031A1
The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5- hydroxytryptamine B1 receptor-stimulating agent, an...  
WO/2017/009491A1
A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is des...  
WO/2017/009487A1
A topical, cosmetic or pharmaceutical, composition comprising a cosmetically or pharmaceutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO.1 or a variant thereof.  
WO/2017/009644A1
An inhibitor of a receptor tyrosine kinase, in particular selected from a compound of formula (I), (II) or (III) as defined in the specification for use in the treatment of fascioscapulohumeral dystrophy (FSHD)wherein formula (I) is exem...  
WO/2017/009472A1
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...  
WO/2017/010382A1
The present invention provides an agent for the treatment of myotonic dystrophy having as an active ingredient at least one compound selected from the group consisting of erythromycin, clarithromycin, and azithromycin, a pharmacologicall...  
WO/2017/004966A1
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...  
WO/2017/004142A1
Provided herein are methods and compositions for the treatment of myopathies.  
WO/2017/000869A1
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...  
WO/2016/207354A1
The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.  
WO/2016/208695A1
Disclosed is a means that can be used for modifying a biologically or pharmacologically active substance from a form incapable of permeating the blood-brain barrier to a form capable of permeating the blood-brain barrier. Also disclosed ...  
WO/2016/203404A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/203405A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/204230A1
A stem cell administration method includes an administration step for injecting a stem cell-containing solution containing stem cells collected from an animal (donor animal) or subcultured stem cells obtained by subculturing the stem cel...  
WO/2016/203406A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/202341A1
The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention furth...  
WO/2016/199878A1
Provided is a sigma-receptor binding agent that is characterized by containing an alkyl ether derivative represented by general formula [1] or a salt thereof. (In the formula, R1 and R2 are the same or different and indicate a hydrogen a...  
WO/2016/197980A1
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffract...  
WO/2016/197945A1
The present invention relates to the use of a composition for preparing a medicament for the treatment of amyotrophic lateral sclerosis and associated disorders. The composition comprises 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceu...  
WO/2016/192657A1
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisom...  
WO/2016/196350A1
The present invention relates to compositions (e.g., AUFl encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of pr...  
WO/2016/195074A1
A read-through therapeutic containing a lincomycin compound as an active ingredient.  
WO/2016/195493A1
Title: Means and methods for treating facioscapulohumeral muscular dystrophy (FSHD). The invention is related to facioscapulohumeral muscular dystrophy (FSHD) and in particular therapeutic means and methods for the treatment of the disea...  
WO/2016/190774A1
Point changes to the 3'UTR nucleotide sequence of the VEGF gene which significantly increase the lifespan of the mRNA transcription product of said gene in mammalian cells have been identified. A gene construct with an optimal list of th...  
WO/2016/187682A1
The present invention relates to a composition based on a mixture of standardised extracts or essential oils of Pterodon pubescens Benth. and Cordia verbenacea DC. Also disclosed are the use thereof and formulations comprising said compo...  
WO/2016/186772A3
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/186772A2
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/184832A1
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the comp...  
WO/2016/181394A1
The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the afor...  
WO/2016/175136A1
The present invention addresses the problem of providing: a novel composition for suppressing muscular fatty change, which contains a component that can be ingested safely for a long period; and others. It is found that quercetin or a gl...  
WO/2016/169028A1
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...  
WO/2016/172224A1
An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding ...  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/170353A1
(3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro -5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.  
WO/2016/166480A1
The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or pre...  
WO/2016/164089A3
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/...  
WO/2016/163912A1
The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth f...  
WO/2016/164501A1
In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type ...  
WO/2016/164497A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4: ActRIIB complexes...  
WO/2016/161343A2
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/157130A1
Macroalgae compositions, processes for the preparation thereof, and applications thereof as a sports nutrition supplement are described. More particularly, a macroalgae composition includes a macroalgae extract including medium chain and...  
WO/2016/158810A1
This agent for the prevention and/or treatment of conditions associated with RAGE/ligand interactions, containing as an active ingredient a compound represented by formula (I): (in the formula, each of the symbols is defined as in the de...  
WO/2016/155661A1
Provided is a compound capable of being used to treat diseases caused by cell proliferation and/or angiogenesis or diseases associated with or accompanied by the cell proliferation and/or the angiogenesis.  
WO/2016/155358A1
Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF proline h...  
WO/2016/161343A3
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/161294A1
Provided herein are methods and kits for increasing cardiac contraction, increasing mitochondrial activity, and/or increasing oxphos activity. Such methods include use of therapeutically effective amounts of one or more agents that incre...  
WO/2016/156470A1
The present invention relates to formulations containing ultra-deformable drug-free particles and their use in treating soft-tissue soreness, such as delayed onset muscle soreness (DOMS) and exercise-induced muscle soreness. The formulat...  
WO/2016/152519A1
Provided is an external medicine for diffuse plexiform neurofibroma. The external medicine for diffuse plexiform neurofibroma according to the present invention comprises as an active ingredient at least one member selected from the grou...  
WO/2016/149092A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2016/148213A1
Disclosed are: any one polypeptide selected from (a) a polypeptide which comprises the amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide which comprises an amino acid sequence produced by deleting, substituting, insertin...  

Matches 251 - 300 out of 23,947